Testing of drugs using human feto-maternal interface organ-on-chips provide insights into pharmacokinetics and efficacy.

ABSTRACT: Objectives: To improve preclinical drug testing during pregnancy, we developed multiple microfluidic organ-on-chip (OOC) devices that represent the structure, functions, and responses of the two feto-maternal interfaces (FMis) in humans (fetal membrane [FMi-OOC] and placenta [PLA-OOC]). This study utilized feto-maternal interface OOCs to test the kinetics and efficacy of drugs during pregnancy. Study design: The FMi-OOC contained amnion epithelial, mesenchymal, chorion trophoblast, and decidual cells. The PLA-OOC contained cytotrophoblasts (BeWo), syncytiotrophoblasts (BeWo + forskolin), and human umbilical vein endothelial cell lines. Therapeutic concentrations of either pravastatin or rosuvastatin (200 ng mL^-1), a model drug for these experiments, were applied to

SUBMITTER: Richardson LS 

PROVIDER: S-EPMC9682442 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature